Paul Richardson, MD, Dana-Farber Cancer Institute

Paul G. Richardson, MD; Nina Shah, MD; David Siegel, MD, PhD; and Saad Z. Usmani, MD, provide closing thoughts and key takeaways on multiple myeloma from the 2020 ASH Virtual Meeting and future directions for disease management. 

Insights on approaching the sequencing of BCMA-targeted agents and whether antigen loss is considered an issue in RRMM. 

Examining non-BCMA BiTE (bispecific T-cell engager) approaches to therapy, such as talquetamab and BFCR4350A, for the treatment of RRMM. 

Exploring other investigational BCMA-targeting agents such as teclistamab, AMG 701, and TNB-383B for the management of RRMM. 

Nina Shah, MD, leads the conversation of using BCMA-targeted antibody-drug conjugate belantamab mafodotin, and the emerging role of CAR T-cell therapy when treating RRMM. 

Paul G. Richardson, MD, reviews early data presented at ASH 2020 on the use of CELMoDs as well as melflufen for the management of RRMM. 

Saad Z. Usmani, MD, leads the discussion on new and updated data for novel PI-based combinations in RRMM as seen in the CANDOR, IKEMA, and BOSTON trials.